Navigation Links
Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
Date:8/6/2008

MEXICO CITY, Aug. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (GSK) announced today that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV medication abacavir. GSK conducted this review upon learning that the analysis undertaken by the D:A:D cohort had found an unexpected but potential association between highly active antiretroviral therapy (HAART) regimens containing abacavir and an increased risk of heart attack. GSK's review of its clinical trial database was presented today at the International AIDS Conference in Mexico City.

The analysis was conducted from a GSK internal database including data from 54 clinical trials. The review pooled data from 9,639 subjects on abacavir-containing HAART and 5,044 subjects on non-abacavir HAART. Overall, less than 30 heart attacks had been reported across the abacavir and non-abacavir groups and no increased risk of heart attack associated with abacavir was observed.

"GSK took the responsibility to examine the existing body of clinical data available to us as soon as we learned the results of the D:A:D cohort," said John Pottage, M.D., Vice President Global Clinical Development at GlaxoSmithKline. "The D:A:D findings were certainly unexpected and are inconsistent with what we have seen with our own data. GSK believes at this time that the D:A:D data are inconclusive."

In the GSK analysis the frequency of coronary artery disorders for both groups was very low and similar to the general population: 2.5 events per 1,000 people in the abacavir HAART and 4 events per 1,000 people in the non-abacavir HAART. Further, the frequency of heart attacks was 1.1 per 1,000 people in the abacavir HAART and 1.4 per 1,000 people in the non-abacavir HAART. GSK's review of clinical and pre-clinical data to date did not reveal a plausible biologic mechanism for the results seen in the D:A:D study.

Inflamma
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: DPLO ... Phil Hagerman , Chairman & CEO, and Sean ... Mr. Hagerman and Mr. Whelan are scheduled ... Boston on Wednesday, September 9, 2015 ... Whelan are also scheduled to participate in the Robert W. ...
(Date:8/31/2015)... AVIV, Israel , August 31, 2015 /PRNewswire/ ... Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or ... and commercializes biomedical innovations in ophthalmology and cancer ... Micromedic Technologies (TASE: MCTC), has identified several new ... of the jawbone in patients treated with bisphosphonate ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... Aug. 31 /PRNewswire/ Reportlinker.com announces that a new ... Insulin Pumps - Global Pipeline ... http://www.reportlinker.com/p0254536/Insulin-Pumps---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... and Market Forecasts to 2016 ...
... (NYSE: HRC ) today announced the appointment ... Chain.  Currently serving as General Manager for Global Lean ... on September 13, 2010.  In addition to his responsibilities ... will be responsible for all aspects of Hill-Rom,s global ...
Cached Medicine Technology:Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain 2
(Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
(Date:8/31/2015)... New York, New York (PRWEB) , ... August 31, 2015 , ... ... eyes to autumn, when play-offs and the World Series will dominate the sports world. ... its division and eventually advance to the final series. For children, especially those who ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... with e-Spirit to future-proof its content management system (CMS) and make website updates ... Digital Sports in making the websites of the Bundesliga (the German equivalent of ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
Breaking Medicine News(10 mins):Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... are the oldest delivery method available, they are ... Several factors have contributed to this trend, the ... of insulin pens. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New analysis ... , European Insulin Delivery Devices Market , ...
... Florida orthopedic surgeon Dr. Steve Meadows is one of the few ... ... Delray Beach, FL (PRWEB) March 17, 2009 -- A breakthrough shoulder ... lost the mobility in their arm from a damaged rotator cuff, ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... President of,Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... on Wednesday, March 18th at 10:10 AM,in the Harbor ... Philips was named President of ... was Vice President and General Manager of Bayer Healthcare ...
... costs that businesses pay to care for one premature baby ... dozen healthy, full-term infants, according to new statistics from the ... healthy full-term babies from birth through their first birthday was ... paid for by health plans, according to the new data. ...
... Inc. , the Northeast Ohio venture development organization that ... Case Technology Ventures (CTV) , a pre-seed stage ... Western Reserve University , recently announced an investment commitment ... Cleveland, OH company commercializing neurostimulation technology developed at ...
Cached Medicine News:Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 2Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 3Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 4Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest 2Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: